2022-2023 Seasonal Influenza Testing and Treatment During the COVID-19 Pandemic

At a glance

During this COCA Call, the presenter will provide an overview of CDC’s recommendations for healthcare providers about influenza diagnostics and the use of antiviral medications for the 2022-2023 influenza season, including considerations during the ongoing COVID-19 pandemic.

Webinar

View slides
View Transcript

Overview

The COVID-19 pandemic disrupted influenza activity during the past two seasons. Since October 2022, influenza activity has increased, signaling an early start to the U.S. influenza season. While it is not possible to predict influenza activity or the severity of the upcoming influenza season in the United States, the Centers for Disease Control and Prevention (CDC) is preparing for co-circulation of influenza and SARS-CoV-2 viruses. While annual influenza vaccination remains the best way to prevent influenza, antiviral medications are an essential addition to vaccination—especially in treating outpatients with suspected or confirmed influenza, people at high risk for influenza complications, those with progressive disease, and hospitalized influenza patients. During this COCA Call, the presenter will provide an overview of CDC's recommendations for healthcare providers about influenza diagnostics and the use of antiviral medications for the 2022-2023 influenza season, including considerations during the ongoing COVID-19 pandemic.

Presenter

Tim Uyeki, MD, MPH, MPP
Chief Medical Officer
Office of the Director
Influenza Division
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention

Call Objectives

COCA Call Objectives

At the conclusion of the session, the participant will be able to accomplish the following:

  1. Cite background information on the topic covered during the presentation.
  2. Discuss CDC's role in the topic covered during the presentation.
  3. Describe the topic's implications for clinicians.
  4. Discuss concerns and/or issues related to preparedness for and/or response to urgent public health threats.
  5. Promote health improvement, wellness, and disease prevention in cooperation with patients, communities, at-risk populations, and other members of an interprofessional team of healthcare providers.

Activity-Specific Objectives:

  1. Discuss background on influenza tests and antivirals for treatment of influenza.
  2. Review influenza testing guidance for patients with acute respiratory illness for the 2022-2023 season, including during community co-circulation of influenza viruses and SARS-CoV-2.
  3. Describe antiviral treatment recommendations for patients with suspected or confirmed influenza for the 2022-2023 season, including during community co-circulation of influenza viruses and SARS-CoV-2.

Continuing Education

To receive continuing education (CE) for WC4520-111522 – Clinician Outreach and Communication Activity (COCA) Calls/Webinars – 2022-2023 Seasonal Influenza Testing and Treatment During the COVID-19 Pandemic, Tuesday, November 15, 2022, please visit TCEO and follow these 9 Simple Steps by Monday, December 19, 2022.

To receive continuing education (CE) for WD4520-111522 – Clinician Outreach and Communication Activity (COCA) Calls/Webinars – 2022-2023 Seasonal Influenza Testing and Treatment During the COVID-19 Pandemic, Tuesday, November 15, 2022, (Web on Demand), please visit TCEO and follow these 9 Simple Steps between Tuesday, December 20, 2022, and Friday, December 20, 2024.

In support of improving patient care, the Centers for Disease Control and Prevention is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Jointly Accredited Provider logo
CDC is a Jointly Accredited Provider in Interprofessional Continuing Education.

CME: The Centers for Disease Control and Prevention designates this activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA CME: The Centers for Disease Control and Prevention has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 12/13/2023. PAs should only claim credit commensurate with the extent of their participation

CNE: The Centers for Disease Control and Prevention designates this activity for 1 nursing contact hours.

CPE: The Centers for Disease Control and Prevention designated this (Knowledge-based) event for pharmacists to receive 0.1 CEUs in pharmacy education. The Universal Activity Number is JA4008229-0000-22-035-L04-P and enduring is JA4008229-0000-22-038-H04-P.

Once credit is claimed, an unofficial statement of credit is immediately available on TCEOnline. Official credit will be uploaded within 60 days on the NABP/CPE Monitor.

CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.1 CEU's for this program.

CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to 1.0 total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 1. Continuing Competency credits available are 1. CDC provider number 98614.

AAVSB/RACE: This program was reviewed and approved by the AAVSB RACE program for 1.0 hours of continuing education. Participants should be aware that some boards have limitations on the number of hours accepted in certain categories and/or restrictions on certain methods of delivery of continuing education. Please contact the AAVSB RACE program at race@aavsb.org if you have any comments/concerns regarding this program's validity or relevancy to the veterinary profession

For Certified Public Health Professionals (CPH): The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 1 CPH recertification credits for this program.

DISCLOSURE: In compliance with continuing education requirements, all planners and presenters must disclose all financial relationships, in any amount, with ineligible companies over the previous 24 months as well as any use of unlabeled product(s) or products under investigational use.

CDC, our planners, and presenters wish to disclose they have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Content will not include any discussion of the unlabeled use of a product or a product under investigational use with the exception of Dr. Tim Uyeki's discussion of antiviral medications for hospitalized patients that are FDA-approved for outpatients.

CDC did not accept financial or in-kind support from ineligible companies for this continuing education activity.

Target Audience

  • Physicians
  • Nurses
  • Pharmacists
  • Veterinarians
  • Physician Assistants
  • Health Educators
  • Other Clinicians

Additional Information

  • Contact Information: coca@cdc.gov
  • Support/Funding: Centers for Disease Control and Prevention, Emergency Risk Communication Branch
  • Method of Participation: You may participate in the educational activity by viewing the program information above.
Print
Content Source: